Newsroom

Oncology

Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA^® (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up

RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median progression-free survival of 8.9 years¹

Additional findings from pooled analysis of three Phase 3 studies showed treatment with ibrutinib has the potential to achieve comparable overall survival to the general European population²

June 14, 2024

Oncology

Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration IMBRUVICA^® (ibrutinib) plus venetoclax as first-line treatment for patients with chronic lymphocytic leukaemia, including those with high-risk disease

At 5 years, 67 percent of patients were progression-free, with overall survival at 96 percent for all treated patients¹

June 14, 2024

Immunology

Johnson & Johnson showcases innovation and leadership in rheumatology at EULAR 2024 Congress

30 abstracts highlight the company’s robust portfolio and commitment to improving outcomes for patients with immune-mediated diseases

Features positive results from a Phase 2 study of nipocalimab in Sjögren’s disease as a late-breaking oral presentation

June 4, 2024

Oncology

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 study in RYBREVANT^® clinical program

Longer overall survival, progression-free survival and duration of response shown with subcutaneous amivantamab; featured in Best of ASCO 2024

RYBREVANT^® marketing application submitted to European Medicines Agency based on PALOMA-3 study

June 3, 2024

Oncology

DARZALEX^® (daratumumab)-based regimens significantly improve clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma

88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with DARZALEX FASPRO^® (daratumumab and hyaluronidase-fihj)-based induction, consolidation and maintenance regimens in the Phase 3 PERSEUS study

7.5 years median overall survival achieved with DARZALEX^®-based regimen in Phase 3 MAIA final analysis is the longest reported in patients ineligible for transplant

June 3, 2024

Oncology

Late-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer

Significantly lower infusion-related reactions seen with subcutaneous amivantamab compared with intravenous administration in new Phase 2 data

June 3, 2024

Oncology

CARVYKTI^® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened responses versus two standard therapies for patients with functional high-risk multiple myeloma

73 percent reduction in risk of disease progression or death seen with CARVYKTI^® in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy¹

June 3, 2024

Immunology

Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis

The Company¹ enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary² for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD)

NM26 has the potential to offer distinctive benefits versus existing treatments and address key unmet needs for AD patientsJ

ohnson & Johnson is committed to developing differentiated bispecific antibodies for treating AD and other immune-mediated diseases

May 28, 2024

Oncology

Johnson & Johnson advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA

PALOMA-3 presentation of subcutaneous amivantamab and lazertinib selected to showcase cutting-edge approaches in lung cancer during prestigious “Best of ASCO” program

New data showcase first- and -best-in-class, complementary multiple myeloma therapies, including DARZALEX^®(daratumumab), CARVYKTI^®(ciltacabtagene autoleucel; cilta-cel), TECVAYLI^®(teclistamab-cqyv) and TALVEY^®(talquetamab-tgvs)

May 23, 2024

Immunology

TREMFYA® (guselkumab) demonstrates superiority versus STELARA® (ustekinumab) in Phase 3 Crohn’s disease program

Data from GALAXI 2 & 3 showed TREMFYA® was superior to STELARA ® in all pooled endoscopic endpoints

May 21, 2024

Search Results

No Results

Recently Viewed

Newsroom

Press Releases